Cost-effectiveness analysis of screening for celiac disease in the adult population

Medical Decision Making

Volumn 26, Issue 3, 2006, Pages 282-293

  Shamir, Raanan ^a,b   Hernell, Olle ^c   Leshno, Moshe ^d  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UMEÅ UNIVERSITY   (Sweden)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Celiac disease; Cost effectiveness analysis; Health economics; Prevention; Screening; Serological markers

Indexed keywords

ENDOMYSIUM ANTIBODY; IMMUNOGLOBULIN A; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY;

ADULT; ARTICLE; CELIAC DISEASE; COST EFFECTIVENESS ANALYSIS; ENDOSCOPY; FOLLOW UP; GLUTEN FREE DIET; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; INTESTINE BIOPSY; LIFE EXPECTANCY; MASS SCREENING; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AUTOANTIBODIES; CELIAC DISEASE; CHILD; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MASS SCREENING;

EID: 33646569110     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X06289012     Document Type: Article

References (59)

1. Walker-Smith JA. Celiac disease. In: Walker WA, Durie PR, Hamilton JR, et al, eds. Pediatric Gastrointestinal Disease. 3rd ed. Hamilton, Ontario: B.C. Decker; 2000; p 727-46.
2. Farrell R, Kelly C. Celiac sprue. N Engl J Med. 2002;346:180-8.
3. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120:636-51.
4. Ciacci C, Cirillo M, Cavallaro R, Mazzacca G. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion. 2002;66:178-85.
5. Trier JS. Diagnosis of celiac sprue. Gastroenterology. 1998;115:211-6.
6. Ivarsson A, Persson LA, Juto P, et al. High prevalence of undiagnosed coeliac disease in adults: a Swedish population-based study. J Intern Med. 1999;245:63-8.
7. Carlsson AK, Axelsson IE, Borulf SK, et al. Serological screening for celiac disease in healthy 2.5-year-old children in Sweden. Pediatrics. 2001;107:42-5.
8. West J, Lloyd A, Reader R, et al. Prevalence of undiagnosed celiac disease in the general population of England. Gastroenterology. 2001;120:A-391.
9. Johnston SD, Watson RGP, McMillan SA, Love AHG. Coeliac disease detected by screening is not silent - simply unrecognized. Q J Med. 1988;91:853-60.
10. Corazza GR, Andreani ML, Biagi F, et al. The smaller size of the 'coeliac iceberg' in adults. Scan J Gastroenterol. 1997;32: 917-9.
11. Maki M, Mustalahti K, Kokkonen J, et al. Prevalence of celiac disease among children in Finland. N Engl J Med. 2003;348:2517-24.
12. Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with celiac disease and their relatives: a cohort study. Lancet. 2001;358:356-61.
13. Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. Gastroenterology. 1989;97:265-71.
14. Nielsen OH, Jacobsen O, Pedersen ER, et al. Non-tropical sprue: malignant disease and mortality rate. Scand J Gastroenterol. 1985;20:13-8.
15. Loftus CG, Loftus EV Jr. Cancer risk in celiac disease. Gastroenterology. 2002;123:1726-35.
16. Askling J, Linet M, Gridley G, Halstensen TS, Ekström K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpeti-formis. Gastroenterology. 2002;123:1428-35.
17. Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002;287:1413-9.
18. Lagerqvist C, Ivarsson A, Juto P, Persson LA, Hernell O. Screening for adult coeliac disease - which serological marker(s) to use? J Int Med. 2001;250:241-8.
19. Ascher H, Hahn-Zoric M, Hanson LA, Kilander AF, Nilsson A, Tlaskalova H. Value of serological markers for clinical diagnosis and population studies of coeliac disease. Scan J Gastroenterol. 1996;31:61-7.
20. Grodzinsky E, Ivarsson A, Juto P, et al. New automated immunoassay measuring immunoglobulin A antigliadin antibodies for prediction of celiac disease in childhood. Clin Diagn Lab Immunol. 2001;8:564-70.
21. Harewood G, Murray JA. Diagnostic approach to a patient with suspected celiac disease: a cost analysis. Digest Dis Sci. 2001;46:2510-4.
22. Logan RFA. Screening for celiac disease - has the time come for mass screening? Acta Pediatr Suppl. 1996;412:15-9.
23. Fasano A. Protagonist, European and North American populations should be screened for coeliac disease. Gut. 2003;52:168-9.
24. Kumar PJ. Antagonist, European and North American populations should be screened for coeliac disease. Gut. 2003;52:170-1.
25. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 2000.
26. Garber AM. Advances in cost effectiveness analysis. In: Culyer AJ, Newhouse JP, eds. Handbook of Health Economics. Vol. 1. New York: Elsevier; 2000. p 181-221.
27. Gold MR, Siegel JE, Russell LB, Weinstein MG, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
28. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
29. Ciclitira PJ, King AL, Fraser JS. AGA technical review on celiac sprue. American Gastroenterological Association. Gastroenterology. 2001;120:1526-40.
30. Carlsson AK, Axelsson IE, Borulf SK, et al. Serological screening for celiac disease in healthy 2.5-year-old children in Sweden. Pediatrics. 2001;107:42-5.
31. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286-92.
32. Weher-Mzell D, Kotanko P, Hauer AC, et al. Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur J Clin Invest. 2004;34:224-8.
33. Cottone M, Termini A, Oliva L, et al. Mortality and causes of death in celiac disease in a Mediterranean area. Digest Dis Sci. 1999;44:2538-47.
34. Peters U, Askling J, Gridley G, et al. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med. 2003;163:1566-72.
35. West J, Logan RFA, Smith CJ, et al. Malignancy and mortality in people with celiac disease: population based cohort study. Br Med J. 2004;329:716-9.
36. Fabiani E, Taccari LM, Ratsch IM, Di Giuseppe S, Coppa GV, Catassi C. Compliance with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year follow-up study. J Pediatr. 2000;136:841-3.
37. Shamir R, Lerner A, Shinar E, Lahat N, Kerner H, Eliakim R. The use of a single serological marker underestimates the prevalence of celiac disease in Israel: a prevalence study of blood donors. Am J Gastroenterol. 2002;97:2589-94.
38. Stern M, for the Working Group on Serologic Screening for Celiac Disease. Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization. J Pediatr Gastroenterol Nutr. 2000;31:513-9.
39. Heudebert GR, Centor RM, Klapow JC, Marks R, Johnson L, Wilcox CM. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med. 2000;15:175-82.
40. Laupacis AD, Feeny AS, Tugwell PX. How attractive does a new technology have to be warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-81.
41. Schuppan D, Hahn EG. Celiac disease and its link to type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001;14(Suppl 1): 597-605.
42. Sigurs N, Johansson C, Elfstrand PO, Viander M, Lanner A. Prevalence of coeliac disease in diabetic children and adolescents in Sweden. Acta Paediatr. 1993;82:748-51.
43. Rapoport MJ, Bistritzer T, Vardi O, Broide E, Azizi A, Vardi P. Increased prevalence of diabetes-related autoantibodies in celiac disease. J Pediatr Gastroenterol Nutr. 1996;23:524-7.
44. Hansen D, Bennedbaek FN, Hansen LK, et al. High prevalence of coeliac disease in Danish children with type I diabetes mellitus. Acta Paediatr. 2001;90:1238-43.
45. Barera G, Bonfanti R, Viscardi M, et al. Occurrence of celiac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study. Pediatrics. 2002;109:833-8.
46. Ventura A, Magazzu G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology. 1999;117:297-3.
47. Counsell CE, Ruddell WS. Association between coeliac disease and autoimmune thyroid disease. Gut. 1995;36:475-6.
48. Valentino R, Savastano S, Tommaselli AP, et al. Prevalence of coeliac disease in patients with thyroid autoimmunity. Horm Res. 1999;51:124-7.
49. Larizza D, Calcaterra V, De Giacomo C, et al. Celiac disease in children with autoimmune thyroid disease. J Pediatr. 2001;139:738-40.
50. Sategna-Guidetti C, Volta U, Ciacci C, et al. Prevalence of thyroid disorders in untreated adult celiac disease patients and effect of gluten withdrawal: an Italian multicenter study. Am J Gastroenterol. 2001;96:751-7.
51. Volta U, Ravaglia G, Granito A, et al. Coeliac disease in patients with autoimmune thyroiditis. Digestion. 2001;64:61-5.
52. Zubillaga P, Vitoria JC, Arrieta A, Echaniz P, Garcia-Masdevall MD. Down's syndrome and celiac disease. J Pediatr Gastroenterol Nutr. 1993;16:168-71.
53. Jansson U, Johansson C. Down syndrome and celiac disease. J Pediatr Gastroenterol Nutr. 1995;21:443-5.
54. Gale L, Wimalaranta H, Brotodiharjo A, Duggan JM. Down's syndrome is strongly associated with coeliac disease. Gut. 1997;40:492-6.
55. Csizmadia CG, Mearin ML, Oren A, et al. Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr. 2000;137:756-61.
56. Catassi C, Fanciulli G, D'Appello AR, et al. Antiendomysium versus antigliadin antibodies in screening the general population for celiac disease. Scand J Gastroenterol. 2000;35:732-6.
57. Shamir R, Eliakim R, Lahat N, Sobel E, Lerner A. ELISA of anti endomysial antibodies in the diagnosis of celiac disease: comparison with immunofluorescence assay of anti endomysial antibodies and tissue transglutaminase antibodies. Isr Med Assoc J. 2002;4:594-6.
58. Hoffenberg EJ, MacKenzie T, Barriga KJ, et al. A prospective study of the incidence of childhood celiac disease. J Pediatr. 2003;143:308-14.
59. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9-17.